Search
Search Funnelback University
1 -
10 of
17
search results for `p53 Activity`
Fully-matching results
-
Professor Sir Alan Fersht FRS | Yusuf Hamied Department of Chemistry
https://www.ch.cam.ac.uk/person/arf2525 Jul 2024: 2019). 21,. 5. (doi:A structure-guided molecular chaperone approach for restoring the transcriptional activity of the p53 cancer mutant Y220C. ... Cancers (Basel). (2019). 11,. 1151. (doi:Aminobenzothiazole derivatives stabilize the thermolabile p53 -
Graduate Poster Display | Pembroke
https://www.pem.cam.ac.uk/college/news/graduate-poster-display24 Jul 2024: Chiba Ene (PhD Medical Sciences) - Histone demethylase Jumonji D3 (JMJD3) as a Tumor Suppressor by Regulating p53 Activity through Lysine Demethylation. -
Alan Fersht | 03 - 05 Sept 2017 Cambridge, UK
https://www.ch.cam.ac.uk/pfei/alan-fersht25 Jul 2024: We focus on how mutation affects proteins in the cell cycle, particularly the tumour suppressor p53, in order to design novel anti-cancer drugs that function by restoring the activity of ... Cancer is a disease of mutation, and the most commonly mutated -
Genome-editing tool could increase cancer risk in cells, say…
https://www.cam.ac.uk/research/news/genome-editing-tool-could-increase-cancer-risk-in-cells-say-researchers11 Jun 2018: Absence of p53 in cells makes them more likely to become tumorous as damage can no longer be corrected. ... The team found that by decreasing activity of p53 in a cell, they could more efficiently edit healthy cells. -
index.html
https://www2.mrc-lmb.cam.ac.uk/groups/fersht/26 Jan 2021: We focus on how mutation affects proteins in the cell cycle, particularly the tumour suppressor p53, in order to design novel anti-cancer drugs that function by restoring the activity of ... Tumour Suppressor p53. Structural Biology and Drug Discovery. -
Ingo Ringshausen | Wellcome-MRC Cambridge Stem Cell Institute
https://www.stemcells.cam.ac.uk/directory/ingo-ringshausen23 Feb 2024: Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. ... Cancer Cell, 2006. 10(6): p. 501-14 PMID:17157790. Christophorou MA, Ringshausen I, Finch AJ, Swigart LB, Evan GI The pathological response to DNA damage does not -
Dr Ingo Ringshausen - Department of Haematology
https://www.haem.cam.ac.uk/staff/senior-staff/dr-ingo-ringshausen/23 Feb 2024: Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPHOS activity in chronic lymphocytic leukemia. ... Swigart, and G.I. Evan. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. -
Alan Fersht - MRC Laboratory of Molecular Biology
https://www2.mrc-lmb.cam.ac.uk/group-leaders/emeritus/alan-fersht/21 Jul 2023: We focus on how mutation affects proteins in the cell cycle, particularly the tumour suppressor p53, in order to design novel anti-cancer drugs that function by restoring the activity of ... Exploiting Transient Protein States for the Design of -
https://www2.mrc-lmb.cam.ac.uk/wp-json/wp/v2/pages/117
https://www2.mrc-lmb.cam.ac.uk/wp-json/wp/v2/pages/117We focus on how mutation affects proteins in the cell cycle, particularly the tumour suppressor p53, in order to design novel anti-cancer drugs that function by restoring the activity of ... n. Cancer is a disease of mutation, and the most commonly -
Dr Suzanne Dawn Turner | Cambridge Immunology Network
https://www.immunology.cam.ac.uk/Networkdirectory/sdturner23 Feb 2024: Lab Investigation doi: 10.1038/labinvest.2011.96 . McDuff F.K.E and Turner S.D.(2011) Aberrant Anaplastic Lymphoma Kinase Activity Induces a p53 and Rb-Dependent Senescence-Like Arrest ... Merkel, O., Morrigl, R.,Turner, S.D. and Kenner, L. (2017)
Refine your results
Format
- 1 pdf
Date
- 10 Past 6 months
- 10 2024
- 10 Past year
- 7 Past 3 months
- 7 Past week
- 7 Past fortnight
- 7 Past month
- 6 Yesterday
- 2 2016
- 1 Uncertain
- 1 2019
- 1 2018
- 1 2023
- 1 2021
Search history
Recently clicked results
Recently clicked results
Your click history is empty.
Recent searches
Recent searches
Your search history is empty.